In the “Dasatinib versus Imatinib Study in Treatment-Naïve CML Patients” (DASISION) phase 3 randomized trial, early molecular responses (EMR: BCR-ABL IS % ≤ 10%) were obtained by 84% of 100 mg QD dasatinib-treated patients and 64% of 400 mg QD imatinib-treated patients [18••]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.